Next Article in Journal / Special Issue
ELISPOT Assay for Monitoring Cytotoxic T Lymphocytes (CTL) Activity in Cancer Vaccine Clinical Trials
Previous Article in Journal / Special Issue
Distinguishing Latent from Active Mycobacterium tuberculosis Infection Using Elispot Assays: Looking Beyond Interferon-gamma
Article Menu

Export Article

Open AccessReview
Cells 2012, 1(2), 100-110;

Role of ELISPOT Assays in Risk Assessment Pre- and Post-Kidney Transplantation

Comprehensive Transplant Center Feinberg School of Medicine, Northwestern University, 303 E Chicago Ave., Tarry Building Suite 11-703, Chicago, IL 60611-3008, USA
Author to whom correspondence should be addressed.
Received: 23 March 2012 / Revised: 30 April 2012 / Accepted: 7 May 2012 / Published: 10 May 2012
(This article belongs to the Special Issue ELISPOT Research)
Full-Text   |   PDF [165 KB, uploaded 10 May 2012]


Immunologic risk in kidney transplantation is typically minimized by avoiding, or at least limiting, the potential of donor specific humoral responses by testing for the presence of donor-specific antibodies (DSA). Additionally, selecting donor and recipient pairs with the least number of human leukocyte antigen (HLA) mismatches has been shown to play a role in transplant outcome. However, numerous other factors may play a role in the success of transplant outcome and patient health. Specifically, the use of T-cell allospecific ELISPOT assays have helped elucidate the role of pre-formed cellular responses as additional factors in post-transplant outcome. In this review, we will evaluate numerous uses of ELISPOT assays to assess the pre- and post-transplant immunologic risk of rejection episodes, graft survival and even viral susceptibility as well as the utility of ELISPOT assays in monitoring tolerance and withdrawal of immunosuppressive medications following kidney transplantation. View Full-Text
Keywords: ELISPOT; kidney; transplant; risk assessment ELISPOT; kidney; transplant; risk assessment
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Zitzner, J.R.; Tambur, A.R. Role of ELISPOT Assays in Risk Assessment Pre- and Post-Kidney Transplantation. Cells 2012, 1, 100-110.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cells EISSN 2073-4409 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top